<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>8 Colon Cancer | 　　　　</title>
  <meta name="description" content="8 Colon Cancer | 　　　　" />
  <meta name="generator" content="bookdown 0.22 and GitBook 2.6.7" />

  <meta property="og:title" content="8 Colon Cancer | 　　　　" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="8 Colon Cancer | 　　　　" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="part-oncology.html"/>
<link rel="next" href="part-others.html"/>
<script src="libs/header-attrs-2.7/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>
<script src="libs/htmlwidgets-1.5.3/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.18/datatables.js"></script>
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="libs/selectize-0.12.0/selectize.min.js"></script>
<link href="libs/dt-plugin-searchhighlight-1.10.20/source.css" rel="stylesheet" />
<script src="libs/dt-plugin-searchhighlight-1.10.20/jquery.highlight.js"></script>
<script src="libs/dt-plugin-searchhighlight-1.10.20/source.min.js"></script>
<link href="libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>
<link href="libs/tabwid-1.0.0/tabwid.css" rel="stylesheet" />




<link rel="stylesheet" href="css/JhengHei.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="index.html#pharmed"><strong>《pharmed》</strong></a></li>
<li><a href="part-chemotherapy.html#part---chemotherapy"><em>Part - Chemotherapy</em></a></li>
<li class="chapter" data-level="1" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html"><i class="fa fa-check"></i><b>1</b> Chemotherapeutic and Biologic Drugs</a>
<ul>
<li class="chapter" data-level="1.1" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#abemaciclib"><i class="fa fa-check"></i><b>1.1</b> Abemaciclib</a></li>
<li class="chapter" data-level="1.2" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#capecitabine"><i class="fa fa-check"></i><b>1.2</b> Capecitabine</a></li>
<li class="chapter" data-level="1.3" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#carboplatin"><i class="fa fa-check"></i><b>1.3</b> Carboplatin</a></li>
<li class="chapter" data-level="1.4" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#fluorouracil"><i class="fa fa-check"></i><b>1.4</b> 5-Fluorouracil</a></li>
<li class="chapter" data-level="1.5" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#oxaliplatin"><i class="fa fa-check"></i><b>1.5</b> Oxaliplatin</a></li>
<li class="chapter" data-level="1.6" data-path="chemotherapeutic-and-biologic-drugs.html"><a href="chemotherapeutic-and-biologic-drugs.html#paclitaxel"><i class="fa fa-check"></i><b>1.6</b> Paclitaxel</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html"><i class="fa fa-check"></i><b>2</b> Common Chemotherapy Regimens</a>
<ul>
<li class="chapter" data-level="2.1" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#adrenocortical-cancer"><i class="fa fa-check"></i><b>2.1</b> ADRENOCORTICAL CANCER</a></li>
<li class="chapter" data-level="2.2" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#anal-cancer"><i class="fa fa-check"></i><b>2.2</b> ANAL CANCER</a></li>
<li class="chapter" data-level="2.3" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#basal-cell-cancer"><i class="fa fa-check"></i><b>2.3</b> BASAL CELL CANCER</a></li>
<li class="chapter" data-level="2.4" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#biliary-tract-cancer"><i class="fa fa-check"></i><b>2.4</b> BILIARY TRACT CANCER</a></li>
<li class="chapter" data-level="2.5" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#bladder-cancer"><i class="fa fa-check"></i><b>2.5</b> BLADDER CANCER</a></li>
<li class="chapter" data-level="2.6" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#brain-cancer"><i class="fa fa-check"></i><b>2.6</b> BRAIN CANCER</a></li>
<li class="chapter" data-level="2.7" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#breast-cancer"><i class="fa fa-check"></i><b>2.7</b> BREAST CANCER</a></li>
<li class="chapter" data-level="2.8" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cancer-of-unknown-primary"><i class="fa fa-check"></i><b>2.8</b> CANCER OF UNKNOWN PRIMARY</a></li>
<li class="chapter" data-level="2.9" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#carcinoid-tumors-and-neuroendocrine-tumors"><i class="fa fa-check"></i><b>2.9</b> CARCINOID TUMORS AND NEUROENDOCRINE TUMORS</a></li>
<li class="chapter" data-level="2.10" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cervical-cancer"><i class="fa fa-check"></i><b>2.10</b> CERVICAL CANCER</a></li>
<li class="chapter" data-level="2.11" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#colorectal-cancer"><i class="fa fa-check"></i><b>2.11</b> COLORECTAL CANCER</a></li>
<li class="chapter" data-level="2.12" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#endometrial-cancer"><i class="fa fa-check"></i><b>2.12</b> ENDOMETRIAL CANCER</a></li>
<li class="chapter" data-level="2.13" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#esophageal-cancer"><i class="fa fa-check"></i><b>2.13</b> ESOPHAGEAL CANCER</a></li>
<li class="chapter" data-level="2.14" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastric-cancer"><i class="fa fa-check"></i><b>2.14</b> GASTRIC CANCER</a></li>
<li class="chapter" data-level="2.15" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastrointestinal-stromal-tumor-gist"><i class="fa fa-check"></i><b>2.15</b> GASTROINTESTINAL STROMAL TUMOR (GIST)</a></li>
<li class="chapter" data-level="2.16" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#head-and-neck-cancer"><i class="fa fa-check"></i><b>2.16</b> HEAD AND NECK CANCER</a></li>
<li class="chapter" data-level="2.17" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#hepatocellular-cancer"><i class="fa fa-check"></i><b>2.17</b> HEPATOCELLULAR CANCER</a></li>
<li class="chapter" data-level="2.18" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#kaposis-sarcoma"><i class="fa fa-check"></i><b>2.18</b> KAPOSI’S SARCOMA</a></li>
<li class="chapter" data-level="2.19" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#leukemia"><i class="fa fa-check"></i><b>2.19</b> LEUKEMIA</a></li>
<li class="chapter" data-level="2.20" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lung-cancer"><i class="fa fa-check"></i><b>2.20</b> LUNG CANCER</a></li>
<li class="chapter" data-level="2.21" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lymphoma"><i class="fa fa-check"></i><b>2.21</b> LYMPHOMA</a></li>
<li class="chapter" data-level="2.22" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-melanoma"><i class="fa fa-check"></i><b>2.22</b> MALIGNANT MELANOMA</a></li>
<li class="chapter" data-level="2.23" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-mesothelioma"><i class="fa fa-check"></i><b>2.23</b> MALIGNANT MESOTHELIOMA</a></li>
<li class="chapter" data-level="2.24" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#merkel-cell-cancer"><i class="fa fa-check"></i><b>2.24</b> MERKEL CELL CANCER</a></li>
<li class="chapter" data-level="2.25" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#multiple-myeloma"><i class="fa fa-check"></i><b>2.25</b> MULTIPLE MYELOMA</a></li>
<li class="chapter" data-level="2.26" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#myelodysplastic-syndrome"><i class="fa fa-check"></i><b>2.26</b> MYELODYSPLASTIC SYNDROME</a></li>
<li class="chapter" data-level="2.27" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#osteogenic-sarcoma"><i class="fa fa-check"></i><b>2.27</b> OSTEOGENIC SARCOMA</a></li>
<li class="chapter" data-level="2.28" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-epithelial"><i class="fa fa-check"></i><b>2.28</b> OVARIAN CANCER (EPITHELIAL)</a></li>
<li class="chapter" data-level="2.29" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-germ-cell"><i class="fa fa-check"></i><b>2.29</b> OVARIAN CANCER (GERM CELL)</a></li>
<li class="chapter" data-level="2.30" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#pancreatic-cancer"><i class="fa fa-check"></i><b>2.30</b> PANCREATIC CANCER</a></li>
<li class="chapter" data-level="2.31" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#prostate-cancer"><i class="fa fa-check"></i><b>2.31</b> PROSTATE CANCER</a></li>
<li class="chapter" data-level="2.32" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#renal-cell-cancer"><i class="fa fa-check"></i><b>2.32</b> RENAL CELL CANCER</a></li>
<li class="chapter" data-level="2.33" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#soft-tissue-sarcomas"><i class="fa fa-check"></i><b>2.33</b> SOFT TISSUE SARCOMAS</a></li>
<li class="chapter" data-level="2.34" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#testicular-cancer"><i class="fa fa-check"></i><b>2.34</b> TESTICULAR CANCER</a></li>
<li class="chapter" data-level="2.35" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thymoma"><i class="fa fa-check"></i><b>2.35</b> THYMOMA</a></li>
<li class="chapter" data-level="2.36" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thyroid-cancer"><i class="fa fa-check"></i><b>2.36</b> THYROID CANCER</a></li>
<li class="chapter" data-level="2.37" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#waldenströms-macroglobulinemia"><i class="fa fa-check"></i><b>2.37</b> WALDENSTRÖM’S MACROGLOBULINEMIA</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html"><i class="fa fa-check"></i><b>3</b> Chemotherapy Dosage Based on Hepatic Function</a>
<ul>
<li class="chapter" data-level="3.1" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html#recommended-dose-reduction-for-hepatic-dysfunction"><i class="fa fa-check"></i><b>3.1</b> Recommended Dose Reduction for Hepatic Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html"><i class="fa fa-check"></i><b>4</b> Chemotherapy Dosage Based on Renal Function</a>
<ul>
<li class="chapter" data-level="4.1" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html#recommended-dose-reduction-for-renal-dysfunction"><i class="fa fa-check"></i><b>4.1</b> Recommended Dose Reduction for Renal Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html"><i class="fa fa-check"></i><b>5</b> Dialysis of Chemotherapy Drugs</a>
<ul>
<li class="chapter" data-level="5.1" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html#guidelines-for-dialysis-of-chemotherapy-drugs"><i class="fa fa-check"></i><b>5.1</b> Guidelines for Dialysis of Chemotherapy Drugs</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html"><i class="fa fa-check"></i><b>6</b> Oncology Performance Status</a>
<ul>
<li class="chapter" data-level="6.1" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#karnofsky-performance"><i class="fa fa-check"></i><b>6.1</b> Karnofsky Performance</a></li>
<li class="chapter" data-level="6.2" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#lansky-performance"><i class="fa fa-check"></i><b>6.2</b> Lansky Performance</a></li>
<li class="chapter" data-level="6.3" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#ecog-performance"><i class="fa fa-check"></i><b>6.3</b> ECOG Performance</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html"><i class="fa fa-check"></i><b>7</b> Common Terminology Criteria for Adverse Events</a>
<ul>
<li class="chapter" data-level="7.1" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html#ctcae-v5.0"><i class="fa fa-check"></i><b>7.1</b> CTCAE v5.0</a></li>
</ul></li>
<li><a href="part-oncology.html#part---oncology"><em>Part - Oncology</em></a></li>
<li class="chapter" data-level="8" data-path="colon-cancer.html"><a href="colon-cancer.html"><i class="fa fa-check"></i><b>8</b> Colon Cancer</a>
<ul>
<li class="chapter" data-level="8.1" data-path="colon-cancer.html"><a href="colon-cancer.html#regimens-for-advanced-or-metastatic-disease"><i class="fa fa-check"></i><b>8.1</b> Regimens for Advanced or Metastatic Disease</a></li>
<li class="chapter" data-level="8.2" data-path="colon-cancer.html"><a href="colon-cancer.html#systemic-therapy-for-advanced-or-metastatic-disease---chemotherapy-regimens"><i class="fa fa-check"></i><b>8.2</b> Systemic Therapy for Advanced or Metastatic Disease - Chemotherapy Regimens</a></li>
</ul></li>
<li><a href="part-others.html#part---others"><em>Part - Others</em></a></li>
<li class="chapter" data-level="9" data-path="icd-10-cm.html"><a href="icd-10-cm.html"><i class="fa fa-check"></i><b>9</b> ICD 10 CM</a>
<ul>
<li class="chapter" data-level="9.1" data-path="icd-10-cm.html"><a href="icd-10-cm.html#國際疾病分類第十版中英對照檢索"><i class="fa fa-check"></i><b>9.1</b> 國際疾病分類第十版中英對照檢索</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="pnce-drp-classification.html"><a href="pnce-drp-classification.html"><i class="fa fa-check"></i><b>10</b> PNCE-DRP Classification</a>
<ul>
<li class="chapter" data-level="10.1" data-path="pnce-drp-classification.html"><a href="pnce-drp-classification.html#pharmaceutical-care-network-europe---classification-for-drug-related-problems-v9.1"><i class="fa fa-check"></i><b>10.1</b> Pharmaceutical Care Network Europe - Classification for Drug related problems V9.1</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="frequently-used-abbreviations.html"><a href="frequently-used-abbreviations.html"><i class="fa fa-check"></i><b>11</b> Frequently Used Abbreviations</a>
<ul>
<li class="chapter" data-level="11.1" data-path="frequently-used-abbreviations.html"><a href="frequently-used-abbreviations.html#medical-abbreviations"><i class="fa fa-check"></i><b>11.1</b> Medical Abbreviations</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="frequently-used-links.html"><a href="frequently-used-links.html"><i class="fa fa-check"></i><b>12</b> Frequently Used Links</a>
<ul>
<li class="chapter" data-level="12.1" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥參考"><i class="fa fa-check"></i><b>12.1</b> 醫藥參考</a></li>
<li class="chapter" data-level="12.2" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥文獻"><i class="fa fa-check"></i><b>12.2</b> 醫藥文獻</a></li>
<li class="chapter" data-level="12.3" data-path="frequently-used-links.html"><a href="frequently-used-links.html#交互作用"><i class="fa fa-check"></i><b>12.3</b> 交互作用</a></li>
<li class="chapter" data-level="12.4" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥物辨識"><i class="fa fa-check"></i><b>12.4</b> 藥物辨識</a></li>
<li class="chapter" data-level="12.5" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥品給付"><i class="fa fa-check"></i><b>12.5</b> 藥品給付</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="memo.html"><a href="memo.html"><i class="fa fa-check"></i><b>13</b> Memo</a>
<ul>
<li class="chapter" data-level="13.1" data-path="memo.html"><a href="memo.html#daily-tasks"><i class="fa fa-check"></i><b>13.1</b> Daily Tasks</a></li>
<li class="chapter" data-level="13.2" data-path="memo.html"><a href="memo.html#print-medical-orders"><i class="fa fa-check"></i><b>13.2</b> Print Medical Orders</a></li>
<li class="chapter" data-level="13.3" data-path="memo.html"><a href="memo.html#brevity-codes"><i class="fa fa-check"></i><b>13.3</b> Brevity Codes</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">　　　　</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="colon-cancer" class="section level1" number="8">
<h1><span class="header-section-number">8</span> Colon Cancer</h1>
<div id="regimens-for-advanced-or-metastatic-disease" class="section level2" number="8.1">
<h2><span class="header-section-number">8.1</span> Regimens for Advanced or Metastatic Disease</h2>
<div id="first-line-therapy" class="section level3" number="8.1.1">
<h3><span class="header-section-number">8.1.1</span> First-Line Therapy</h3>
<ul>
<li><p>FOLFOX</p>
<ul>
<li>FOLFOX</li>
<li>FOLFOX/bevacizumab</li>
<li>FOLFOX/cetuximab</li>
<li>FOLFOX/panitumumab</li>
</ul></li>
<li><p>CapeOx</p>
<ul>
<li>CapeOx</li>
<li>CapeOx/bevacizumab</li>
</ul></li>
<li><p>FOLFIRI</p>
<ul>
<li>FOLFIRI</li>
<li>FOLFIRI/bevacizumab</li>
<li>FOLFIRI/cetuximab</li>
<li>FOLFIRI/panitumumab</li>
</ul></li>
<li><p>FOLFOXIRI</p>
<ul>
<li>FOLFOXIRI</li>
<li>FOLFOXIRI/bevacizumab</li>
</ul></li>
<li><p>Nivolumab</p></li>
<li><p>Pembrolizumab</p></li>
<li><p>Nivolumab/ipilimumab</p></li>
<li><p>5-FU/leucovorin</p>
<ul>
<li>5-FU/leucovorin</li>
<li>5-FU/leucovorin/bevacizumab</li>
</ul></li>
<li><p>Capecitabine</p>
<ul>
<li>Capecitabine</li>
<li>Capecitabine/bevacizumab</li>
</ul></li>
<li><p>Cetuximab</p></li>
<li><p>Panitumumab</p></li>
<li><p>Trastuzumab/Pertuzumab</p></li>
<li><p>Trastuzumab/Lapatinib</p></li>
<li><p>Fam-trastuzumab deruxtecan-nxki</p></li>
</ul>
</div>
<div id="second_line-therapy" class="section level3" number="8.1.2">
<h3><span class="header-section-number">8.1.2</span> Second_Line Therapy</h3>
<ul>
<li><p>FOLFIRI</p>
<ul>
<li>FOLFIRI</li>
<li>FOLFIRI/bevacizumab (after prior bevacizumab)</li>
<li>FOLFIRI/bevacizumab (no prior bevacizumab)</li>
<li>FOLFIRI/ziv-aflibercept (after prior bevacizumab)</li>
<li>FOLFIRI/ziv-aflibercept (no prior bevacizumab)</li>
<li>FOLFIRI/ramucirumab (after prior bevacizumab)</li>
<li>FOLFIRI/ramucirumab (no prior bevacizumab)</li>
<li>FOLFIRI/cetuximab</li>
<li>FOLFIRI/panitumumab</li>
</ul></li>
<li><p>Irinotecan</p>
<ul>
<li>Irinotecan</li>
<li>Irinotecan/cetuximab</li>
<li>Irinotecan/panitumumab</li>
</ul></li>
<li><p>Encorafenib/cetuximab</p></li>
<li><p>Encorafenib/panitumumab</p></li>
<li><p>Larotrectinib</p></li>
<li><p>Entrectinib</p></li>
<li><p>Irinotecan</p>
<ul>
<li>Irinotecan/bevacizumab (after prior bevacizumab)</li>
<li>Irinotecan/bevacizumab (no prior bevacizumab)</li>
<li>Irinotecan/ziv-aflibercept (after prior bevacizumab)</li>
<li>Irinotecan/ziv-aflibercept (no prior bevacizumab)</li>
<li>Irinotecan/ramucirumab (after prior bevacizumab)</li>
<li>Irinotecan/ramucirumab (no prior bevacizumab)</li>
<li>Irinotecan/oxaliplatin</li>
</ul></li>
<li><p>IROX</p>
<ul>
<li>IROX/bevacizumab (after prior bevacizumab)</li>
<li>IROX/bevacizumab (no prior bevacizumab)</li>
</ul></li>
<li><p>Nivolumab</p></li>
<li><p>Pembrolizumab</p></li>
<li><p>Nivolumab/ipilimumab</p></li>
<li><p>Trastuzumab/pertuzumab</p></li>
<li><p>Trastuzumab/lapatinib</p></li>
<li><p>Fam-trastuzumab deruxtecan-nxki</p></li>
<li><p>FOLFOX</p>
<ul>
<li>FOLFOX</li>
<li>FOLFOX/bevacizumab (after prior bevacizumab)</li>
<li>FOLFOX/bevacizumab (no prior bevacizumab)</li>
</ul></li>
<li><p>CapeOx</p>
<ul>
<li>CapeOx/bevacizumab (after prior bevacizumab)</li>
<li>CapeOx/bevacizumab (no prior bevacizumab)</li>
</ul></li>
<li><p>Regorafenib</p></li>
<li><p>Trifluridine/tipiracil</p></li>
<li><p>Trifluridine/tipiracil/bevacizumab</p></li>
<li><p>CapeOx</p></li>
<li><p>Panitumumab</p></li>
<li><p>Cetuximab</p></li>
</ul>
</div>
<div id="third_line-therapy" class="section level3" number="8.1.3">
<h3><span class="header-section-number">8.1.3</span> Third_Line Therapy</h3>
<ul>
<li><p>CapeOx</p></li>
<li><p>Cetuximab</p></li>
<li><p>FOLFOX</p></li>
<li><p>Irinotecan</p>
<ul>
<li>Irinotecan</li>
<li>Irinotecan/cetuximab</li>
<li>Irinotecan/panitumumab</li>
</ul></li>
<li><p>Encorafenib/cetuximab</p></li>
<li><p>Encorafenib/panitumumab</p></li>
<li><p>Larotrectinib</p></li>
<li><p>Entrectinib</p></li>
<li><p>Nivolumab</p></li>
<li><p>Pembrolizumab</p></li>
<li><p>Nivolumab/ipilimumab</p></li>
<li><p>Trastuzumab/pertuzumab</p></li>
<li><p>Trastuzumab/lapatinib</p></li>
<li><p>Fam-trastuzumab deruxtecan-nxki</p></li>
<li><p>Panitumumab</p></li>
<li><p>Regorafenib (previous trifluridine/tipiracil)</p></li>
<li><p>Regorafenib (no previous trifluridine/tipiracil)</p></li>
<li><p>Trifluridine/tipiracil (previous regorafenib)</p></li>
<li><p>Trifluridine/tipiracil (no previous regorafenib)</p></li>
<li><p>Trifluridine/tipiracil/bevacizumab (previous regorafenib)</p></li>
<li><p>Trifluridine/tipiracil/bevacizumab (no previous regorafenib)</p></li>
</ul>
</div>
</div>
<div id="systemic-therapy-for-advanced-or-metastatic-disease---chemotherapy-regimens" class="section level2" number="8.2">
<h2><span class="header-section-number">8.2</span> Systemic Therapy for Advanced or Metastatic Disease - Chemotherapy Regimens</h2>
<div id="folfox" class="section level3" number="8.2.1">
<h3><span class="header-section-number">8.2.1</span> FOLFOX</h3>
<div id="mfolfox-6" class="section level4" number="8.2.1.1">
<h4><span class="header-section-number">8.2.1.1</span> mFOLFOX 6</h4>
<ul>
<li>Oxaliplatin 85 mg/m2 IV day 1</li>
<li>Leucovorin 400 mg/m2 IV day 1</li>
<li>5-FU 400 mg/m2 IV bolus on day 1,
<ul>
<li>followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) IV continuous infusion</li>
</ul></li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="mfolfox-7" class="section level4" number="8.2.1.2">
<h4><span class="header-section-number">8.2.1.2</span> mFOLFOX 7</h4>
<ul>
<li>Oxaliplatin 85 mg/m2 IV day 1</li>
<li>Leucovorin 400 mg/m2 IV day 1</li>
<li>5-FU 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) IV continuous infusion</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfox-bevacizumab" class="section level4" number="8.2.1.3">
<h4><span class="header-section-number">8.2.1.3</span> FOLFOX + bevacizumab</h4>
<ul>
<li>Bevacizumab 5 mg/kg IV, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfox-panitumumab" class="section level4" number="8.2.1.4">
<h4><span class="header-section-number">8.2.1.4</span> FOLFOX + panitumumab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Panitumumab 6 mg/kg IV over 60 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfox-cetuximab" class="section level4" number="8.2.1.5">
<h4><span class="header-section-number">8.2.1.5</span> FOLFOX + cetuximab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Cetuximab 400 mg/m2 IV over 2 hours first infusion,
<ul>
<li>followed by 250 mg/m2 IV over 60 minutes weekly</li>
</ul></li>
</ul>
<p>or</p>
<ul>
<li>Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks</li>
</ul>
</div>
</div>
<div id="capeox" class="section level3" number="8.2.2">
<h3><span class="header-section-number">8.2.2</span> CAPEOX</h3>
<ul>
<li>Oxaliplatin 130 mg/m2 IV day 1</li>
<li>Capecitabine 1000 mg/m2 twice daily PO for 14 days</li>
<li>Repeat every 3 weeks</li>
</ul>
<div id="capeox-bevacizumab" class="section level4" number="8.2.2.1">
<h4><span class="header-section-number">8.2.2.1</span> CAPEOX + bevacizumab</h4>
<ul>
<li>Oxaliplatin 130 mg/m2 IV day 1</li>
<li>Capecitabine 1000bb mg/m2 PO twice daily for 14 days</li>
<li>Bevacizumab 7.5 mg/kg IV day 1</li>
<li>Repeat every 3 weeks</li>
</ul>
</div>
</div>
<div id="folfiri" class="section level3" number="8.2.3">
<h3><span class="header-section-number">8.2.3</span> FOLFIRI</h3>
<ul>
<li>Irinotecan 180 mg/m2 IV over 30–90 minutes, day 1</li>
<li>Leucovorinaa 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1</li>
<li>5-FU 400 mg/m2 IV bolus day 1,
<ul>
<li>followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) continuous infusion</li>
</ul></li>
<li>Repeat every 2 weeks</li>
</ul>
<div id="folfiri-bevacizumab-1" class="section level4" number="8.2.3.1">
<h4><span class="header-section-number">8.2.3.1</span> FOLFIRI + bevacizumab</h4>
<ul>
<li>Bevacizumab 5 mg/kg IV, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfiri-cetuximab-1" class="section level4" number="8.2.3.2">
<h4><span class="header-section-number">8.2.3.2</span> FOLFIRI + cetuximab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Cetuximab 400 mg/m2 IV over 2 hours first infusion,
<ul>
<li>followed by 250 mg/m2 IV over 60 minutes weekly</li>
</ul></li>
</ul>
<p>or</p>
<ul>
<li>Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks</li>
</ul>
</div>
<div id="folfiri-panitumumab-1" class="section level4" number="8.2.3.3">
<h4><span class="header-section-number">8.2.3.3</span> FOLFIRI + panitumumab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Panitumumab 6 mg/kg IV over 60 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfiri-ziv-aflibercept-1" class="section level4" number="8.2.3.4">
<h4><span class="header-section-number">8.2.3.4</span> FOLFIRI + ziv-aflibercept</h4>
<ul>
<li>Ziv-aflibercept 4 mg/kg IV over 60 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfiri-ramucirumab-1" class="section level4" number="8.2.3.5">
<h4><span class="header-section-number">8.2.3.5</span> FOLFIRI + ramucirumab</h4>
<ul>
<li>Ramucirumab 8 mg/kg over 60 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
</div>
<div id="folfoxiri-1" class="section level3" number="8.2.4">
<h3><span class="header-section-number">8.2.4</span> FOLFOXIRI</h3>
<ul>
<li>Irinotecan 165 mg/m2 IV day 1,</li>
<li>Oxaliplatin 85 mg/m2 IV day 1,</li>
<li>Leucovorin 400 mg/m2 day 1,</li>
<li>Fluorouracil 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion starting on day 1.</li>
<li>Repeat every 2 weeks</li>
<li>The dose used in European studies was 3200 mg/m2. U.S. patients have been shown to have poorer tolerance for 5-FU. The dose listed above is recommended for U.S. patients.</li>
</ul>
<div id="folfoxiri-bevacizumab-1" class="section level4" number="8.2.4.1">
<h4><span class="header-section-number">8.2.4.1</span> FOLFOXIRI + bevacizumab</h4>
<ul>
<li>Bevacizumab 5 mg/kg IV, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfoxiri-cetuximab" class="section level4" number="8.2.4.2">
<h4><span class="header-section-number">8.2.4.2</span> FOLFOXIRI + cetuximab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Cetuximab 400 mg/m2 IV over 2 hours first infusion,
<ul>
<li>followed by 250 mg/m2 IV over 60 minutes weekly</li>
</ul></li>
</ul>
<p>or</p>
<ul>
<li>Cetuximab 500 mg/m2 IV over 2 hours, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="folfoxiri-panitumumab-1" class="section level4" number="8.2.4.3">
<h4><span class="header-section-number">8.2.4.3</span> FOLFOXIRI + panitumumab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Panitumumab 6 mg/kg IV over 60 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
</div>
<div id="irox" class="section level3" number="8.2.5">
<h3><span class="header-section-number">8.2.5</span> IROX</h3>
<ul>
<li>Oxaliplatin 85 mg/m2 IV,
<ul>
<li>followed by irinotecan 200 mg/m2 over 30–90 minutes every 3 weeks</li>
</ul></li>
</ul>
<div id="irox-bevacizumab" class="section level4" number="8.2.5.1">
<h4><span class="header-section-number">8.2.5.1</span> IROX + bevacizumab</h4>
<ul>
<li>Bevacizumab 7.5 mg/kg IV on day 1</li>
<li>Repeat every 3 weeks</li>
</ul>
</div>
</div>
<div id="fu" class="section level3" number="8.2.6">
<h3><span class="header-section-number">8.2.6</span> 5-FU</h3>
<div id="bolus-or-infusional-5-fuleucovorin" class="section level4" number="8.2.6.1">
<h4><span class="header-section-number">8.2.6.1</span> Bolus or infusional 5-FU/leucovorin</h4>
<ul>
<li>Roswell Park regimen</li>
<li>Leucovorin 500 mg/m2 IV over 2 hours, days 1, 8, 15, 22, 29, and 36</li>
<li>5-FU 500 mg/m2 IV bolus 1 hour after start of leucovorin, days 1, 8, 15, 22, 29, and 36</li>
<li>Repeat every 8 weeks</li>
</ul>
</div>
<div id="simplified-biweekly-infusional-5-fulv-slv5fu2" class="section level4" number="8.2.6.2">
<h4><span class="header-section-number">8.2.6.2</span> Simplified biweekly infusional 5-FU/LV (sLV5FU2)</h4>
<ul>
<li>Leucovorin 400 mg/m2 IV over 2 hours on day 1,
<ul>
<li>followed by 5-FU bolus 400 mg/m2 followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) continuous infusion</li>
</ul></li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
<div id="weekly" class="section level4" number="8.2.6.3">
<h4><span class="header-section-number">8.2.6.3</span> Weekly</h4>
<ul>
<li>Leucovorin 20 mg/m2 IV over 2 hours on day 1,</li>
<li>5-FU 500 mg/m2 IV bolus injection 1 hour after the start of leucovorin.</li>
<li>Repeat weekly.</li>
</ul>
<p>or</p>
<ul>
<li>5-FU 2600 mg/m2 by 24-hour infusion plus leucovorin 500 mg/m2</li>
<li>Repeat every week.</li>
</ul>
</div>
<div id="bolus-or-infusional-5-fu-bevacizumab" class="section level4" number="8.2.6.4">
<h4><span class="header-section-number">8.2.6.4</span> Bolus or infusional 5-FU + bevacizumab</h4>
<ul>
<li>Bevacizumab 5 mg/kg IV on Day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
</div>
<div id="capecitabine-8" class="section level3" number="8.2.7">
<h3><span class="header-section-number">8.2.7</span> Capecitabine</h3>
<ul>
<li>Capecitabine 850–1250 mg/m2 PO twice daily for 14 days</li>
<li>Repeat every 3 weeks</li>
</ul>
<div id="capecitabine-bevacizumab" class="section level4" number="8.2.7.1">
<h4><span class="header-section-number">8.2.7.1</span> Capecitabine + bevacizumab</h4>
<ul>
<li>Bevacizumab 7.5 mg/kg IV, day 1</li>
<li>Repeat every 3 weeks</li>
</ul>
</div>
</div>
<div id="irinotecan-2" class="section level3" number="8.2.8">
<h3><span class="header-section-number">8.2.8</span> Irinotecan</h3>
<ul>
<li>Irinotecan 125 mg/m2 IV over 30–90 minutes, days 1 and 8</li>
<li>Repeat every 3 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Irinotecan 180 mg/m2 IV over 30–90 minutes, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Irinotecan 300–350 mg/m2 IV over 30–90 minutes, day 1</li>
<li>Repeat every 3 weeks</li>
</ul>
<div id="irinotecan-cetuximab-1" class="section level4" number="8.2.8.1">
<h4><span class="header-section-number">8.2.8.1</span> Irinotecan + cetuximab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Cetuximab 400 mg/m2 first infusion,
<ul>
<li>followed by 250 mg/m2 IV weekly</li>
</ul></li>
</ul>
<p>or</p>
<ul>
<li>Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks</li>
</ul>
</div>
<div id="irinotecan-panitumumab" class="section level4" number="8.2.8.2">
<h4><span class="header-section-number">8.2.8.2</span> Irinotecan + panitumumab</h4>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Panitumumab 6 mg/kg IV over 60 minutes every 2 weeks</li>
</ul>
</div>
<div id="irinotecan-bevacizumab-1" class="section level4" number="8.2.8.3">
<h4><span class="header-section-number">8.2.8.3</span> Irinotecan + bevacizumab</h4>
<ul>
<li>Irinotecan 180 mg/m2 IV, day 1</li>
<li>Bevacizumab 5 mg/kg IV, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Irinotecan 300–350 mg/m2 IV, day 1</li>
<li>Bevacizumab 7.5 mg/kg IV, day 1</li>
<li>Repeat every 3 weeks</li>
</ul>
</div>
<div id="irinotecan-ramucirumab" class="section level4" number="8.2.8.4">
<h4><span class="header-section-number">8.2.8.4</span> Irinotecan + ramucirumab</h4>
<ul>
<li>Ramucirumab 8 mg/kg IV over 60 minutes every 2 weeks</li>
</ul>
</div>
<div id="irinotecan-ziv-aflibercept" class="section level4" number="8.2.8.5">
<h4><span class="header-section-number">8.2.8.5</span> Irinotecan + ziv-aflibercept</h4>
<ul>
<li>Irinotecan 180 mg/m2 IV, day 1</li>
<li>Ziv-aflibercept 4 mg/kg IV, day 1</li>
<li>Repeat every 2 weeks</li>
</ul>
</div>
</div>
<div id="cetuximab-3" class="section level3" number="8.2.9">
<h3><span class="header-section-number">8.2.9</span> Cetuximab</h3>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Cetuximab 400 mg/m2 first infusion,
<ul>
<li>followed by 250 mg/m2 IV weekly</li>
</ul></li>
</ul>
<p>or</p>
<ul>
<li>Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks</li>
</ul>
</div>
<div id="panitumumab-1" class="section level3" number="8.2.10">
<h3><span class="header-section-number">8.2.10</span> Panitumumab</h3>
<blockquote>
<p>(KRAS/NRAS/BRAF WT only)</p>
</blockquote>
<ul>
<li>Panitumumab 6 mg/kg IV over 60 minutes every 2 weeks</li>
</ul>
</div>
<div id="regorafenib-3" class="section level3" number="8.2.11">
<h3><span class="header-section-number">8.2.11</span> Regorafenib</h3>
<ul>
<li>Regorafenib 160 mg PO daily on days 1–21</li>
</ul>
<p>or</p>
<ul>
<li>First cycle: Regorafenib 80 mg PO daily on days 1–7,
<ul>
<li>followed by 120 mg PO daily on days 8–14,</li>
<li>followed by 160 mg PO daily on days 15–21</li>
</ul></li>
<li>Subsequent cycles: Regorafenib 160 mg PO daily on days 1–21</li>
<li>Repeat every 28 days</li>
</ul>
</div>
<div id="trifluridine-tipiracil-bevacizumab" class="section level3" number="8.2.12">
<h3><span class="header-section-number">8.2.12</span> Trifluridine + tipiracil ± bevacizumab</h3>
<ul>
<li>Trifluridine + tipiracil 35 mg/m2 up to a maximum dose of 80 mg per dose (based on the trifluridine component) PO twice daily days 1–5 and 8–12</li>
<li>Bevacizumab 5 mg/kg on days 1 and 15</li>
<li>Repeat every 28 days</li>
</ul>
</div>
<div id="pembrolizumab-13" class="section level3" number="8.2.13">
<h3><span class="header-section-number">8.2.13</span> Pembrolizumab</h3>
<blockquote>
<p>(dMMR/MSI-H only)</p>
</blockquote>
<ul>
<li>Pembrolizumab 2 mg/kg IV every 3 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Pembrolizumab 200 mg IV every 3 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Pembrolizumab 400 mg IV every 6 weeks</li>
</ul>
</div>
<div id="nivolumab-9" class="section level3" number="8.2.14">
<h3><span class="header-section-number">8.2.14</span> Nivolumab</h3>
<blockquote>
<p>(dMMR/MSI-H only)</p>
</blockquote>
<ul>
<li>Nivolumab 3 mg/kg every 2 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Nivolumab 240 mg IV every 2 weeks</li>
</ul>
<p>or</p>
<ul>
<li>Nivolumab 480 mg IV every 4 weeks</li>
</ul>
<div id="nivolumab-ipilimumab-3" class="section level4" number="8.2.14.1">
<h4><span class="header-section-number">8.2.14.1</span> Nivolumab + ipilimumab</h4>
<blockquote>
<p>(dMMR/MSI-H only)</p>
</blockquote>
<ul>
<li>Nivolumab 3 mg/kg (30-minute IV infusion) and ipilimumab 1 mg/kg (30-minute IV infusion) once every 3 weeks for four doses,
<ul>
<li>followed by Nivolumab 3 mg/kg IV or nivolumab 240 mg IV every 2 weeks or Nivolumab 480 mg IV every 4 weeks</li>
</ul></li>
</ul>
</div>
</div>
<div id="trastuzumab-1" class="section level3" number="8.2.15">
<h3><span class="header-section-number">8.2.15</span> Trastuzumab</h3>
<div id="trastuzumab-pertuzumab" class="section level4" number="8.2.15.1">
<h4><span class="header-section-number">8.2.15.1</span> Trastuzumab + pertuzumab</h4>
<blockquote>
<p>(HER2-amplified and RAS and BRAF WT)</p>
</blockquote>
<ul>
<li>Trastuzumab 8 mg/kg IV loading dose on day 1 of cycle 1,
<ul>
<li>followed by 6 mg/kg IV every 21 days</li>
</ul></li>
<li>Pertuzumab 840 mg IV loading dose on day 1 of cycle 1,
<ul>
<li>followed by 420 mg IV every 21 days</li>
</ul></li>
</ul>
</div>
<div id="trastuzumab-lapatinib-1" class="section level4" number="8.2.15.2">
<h4><span class="header-section-number">8.2.15.2</span> Trastuzumab + lapatinib</h4>
<blockquote>
<p>(HER2-amplified and RAS and BRAF WT)</p>
</blockquote>
<ul>
<li>Trastuzumab 4 mg/kg IV loading dose on day 1 of cycle 1,
<ul>
<li>followed by 2 mg/kg IV weekly</li>
</ul></li>
<li>Lapatinib 1000 mg PO daily</li>
</ul>
</div>
</div>
<div id="fam-trastuzumab-deruxtecan-nxki" class="section level3" number="8.2.16">
<h3><span class="header-section-number">8.2.16</span> Fam-trastuzumab deruxtecan-nxki</h3>
<ul>
<li>Fam-trastuzumab deruxtecan-nxki 6.4 mg/kg IV on Day 1</li>
<li>Repeat every 21 days</li>
</ul>
</div>
<div id="encorafenib" class="section level3" number="8.2.17">
<h3><span class="header-section-number">8.2.17</span> Encorafenib</h3>
<div id="encorafenib-cetuximab" class="section level4" number="8.2.17.1">
<h4><span class="header-section-number">8.2.17.1</span> Encorafenib + cetuximab</h4>
<blockquote>
<p>(BRAF V600E mutation positive)</p>
</blockquote>
<ul>
<li>Encorafenib 300 mg PO daily</li>
<li>Cetuximab 400 mg/m2 followed by 250 mg/m2 weekly</li>
</ul>
</div>
<div id="encorafenib-panitumumab" class="section level4" number="8.2.17.2">
<h4><span class="header-section-number">8.2.17.2</span> Encorafenib + panitumumab</h4>
<blockquote>
<p>(BRAF V600E mutation positive)</p>
</blockquote>
<ul>
<li>Encorafenib 300 mg PO daily</li>
<li>Panitumumab 6 mg/kg IV every 14 days</li>
</ul>
</div>
</div>
<div id="larotrectinib" class="section level3" number="8.2.18">
<h3><span class="header-section-number">8.2.18</span> Larotrectinib</h3>
<blockquote>
<p>(NTRK gene fusion positive)</p>
</blockquote>
<ul>
<li>Larotrectinib 100 mg PO twice daily</li>
</ul>
</div>
<div id="entrectinib" class="section level3" number="8.2.19">
<h3><span class="header-section-number">8.2.19</span> Entrectinib</h3>
<blockquote>
<p>(NTRK gene fusion positive)</p>
</blockquote>
<ul>
<li>Entrectinib 600 mg PO once daily</li>
</ul>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="part-oncology.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="part-others.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
